Results 151 to 160 of about 33,428 (239)

The dual role of BRD9 in cancer: Mechanistic insights and therapeutic prospects. [PDF]

iScience
Li J, Dai W, Cao F, Hou W, Zhou X, Liang W, Xie F, Fu Y, Xie Z, Liu S.   +9 more
europepmc   +1 more source

Correction of the molecular phenotype of X-linked Dystonia-Parkinsonism reveals a non-canonical function of BRD4. [PDF]

Nat Commun
Capponi S, Ehret S, Camgöz Z, Gather F, Vaine CA, Özyerli-Göknar E, Follo M, Bragg DC, Vogel T, Timmers HTM.   +9 more
europepmc   +1 more source

New leap of BRD9 inhibitor: Imidazole substituents making BRD9 inhibitors excellent drug candidates for AML. [PDF]

Acta Pharm Sin B
Zhou E.
europepmc   +1 more source

Histone modification cross-talk: analytical tools and molecular mechanisms. [PDF]

Biochem J
Jiang J, DuBois-Coyne S, Nam E, Whedon SD, Lee K, Cole PA.   +5 more
europepmc   +1 more source

De novo protein-ligand design including protein flexibility and conformational adaptation. [PDF]

Bioinformatics
Agamia J, Zacharias M.
europepmc   +1 more source

Bromodomain-containing protein 4 in inflammatory diseases: molecular mechanisms and therapeutic potential. [PDF]

J Inflamm (Lond)
Frascatani R, Marafini I, Colella M, Monteleone G.   +3 more
europepmc   +1 more source

Discovery of molecular glues that bind FKBP12 and structurally distinct targets using DNA-encoded libraries. [PDF]

Nat Commun
Zandi TA, Romanowski MJ, Viscomi JS, Gunderson K, Tan ZY, Tong B, Bonazzi S, Zécri FJ, Schreiber SL, Michaud GA.   +9 more
europepmc   +1 more source

Structural Basis for BD1-Preferring 2,4-Disubstituted Pyrimidine BRDT Inhibitors. [PDF]

J Med Chem
Liang T, Guan X, Chan A, Kalra P, Shi R, Solberg J, Sigua LH, Qi J, Pomerantz WCK, Schönbrunn E, Hawkinson JE, Georg GI.   +11 more
europepmc   +1 more source

[Retracted] Clinical significance of bromodomain-containing protein 7 and its association with tumor progression in prostate cancer. [PDF]

Oncol Lett
Liang Y, Dong B, Shen J, Ma C, Ma Z.
europepmc   +1 more source

Perturbation of BRD4 and p300 activity suppresses super enhancer‑driven <i>KLF6</i> expression in renal carcinoma. [PDF]

Oncol Rep
Zamberi NNM, Abuhamad AY, Yusuf SNHM, Rahman NQAA, Mohtar MA, Syafruddin SE.   +5 more
europepmc   +1 more source